Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

106.49
-1.3000-1.21%
Post-market: 106.490.00000.00%19:37 EDT
Volume:1.01M
Turnover:108.82M
Market Cap:9.39B
PE:-52.98
High:110.00
Open:108.85
Low:105.71
Close:107.79
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:1.19
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:9.83
PE(LYR):-53.91

Loading ...

Spyre Therapeutics - Material Deal Triggers End of Dosing Restrictions Outside Initial Field After June 1, 2028 - SEC Filing

THOMSON REUTERS
·
Jun 02

Spyre Therapeutics shareholders approve amended employee stock purchase plan at annual meeting

Reuters
·
May 30

Spyre Therapeutics to Present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire
·
May 27

LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

TIPRANKS
·
May 18

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), DocGo (DCGO) and Spyre Therapeutics (SYRE)

TIPRANKS
·
May 12

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 10

Spyre Therapeutics Director Michael Thomas Henderson sells USD 5.87 million common shares

Reuters
·
May 09

Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

TIPRANKS
·
May 07

Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders

TIPRANKS
·
May 06

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)

TIPRANKS
·
May 06

Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, vs. FactSet Est of $0.67 Loss

MT Newswires Live
·
May 05

Spyre Q1 FY26 net loss widens to $69 million; R&D expenses rise to $60.4 million

Reuters
·
May 05

Spyre Therapeutics Inc - Reports Cash, Cash Equivalents, and Marketable Securities of $741.5 Mln as of March 31, 2026,Expected Runway Into H2 2029

THOMSON REUTERS
·
May 05

Spyre Therapeutics, Inc. Q1 Basic EPS USD -29.66

THOMSON REUTERS
·
May 05

Spyre Therapeutics, Inc. Q1 Operating Expenses USD 45.641 Million

THOMSON REUTERS
·
May 05

Corrected-Spyre Therapeutics, Inc. Q1 Basic EPS USD -0.74 (Corrects Amount)

THOMSON REUTERS
·
May 05

Press Release: Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 05

Spyre Therapeutics CFO Scott Burrows disposes 12,500 shares worth $892,125

Reuters
·
May 02